ADCC Enhanced Antibody - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

TABLE OF CONTENTS

1 Market Overview

• 1.1 ADCC Enhanced Antibody Product Introduction
• 1.2 Global ADCC Enhanced Antibody Market Size Forecast
  • 1.2.1 Global ADCC Enhanced Antibody Sales Value (2020-2031)
  • 1.2.2 Global ADCC Enhanced Antibody Sales Volume (2020-2031)
  • 1.2.3 Global ADCC Enhanced Antibody Sales Price (2020-2031)
• 1.3 ADCC Enhanced Antibody Market Trends & Drivers
  • 1.3.1 ADCC Enhanced Antibody Industry Trends
  • 1.3.2 ADCC Enhanced Antibody Market Drivers & Opportunity
  • 1.3.3 ADCC Enhanced Antibody Market Challenges
  • 1.3.4 ADCC Enhanced Antibody Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global ADCC Enhanced Antibody Players Revenue Ranking (2024)
• 2.2 Global ADCC Enhanced Antibody Revenue by Company (2020-2025)
• 2.3 Global ADCC Enhanced Antibody Players Sales Volume Ranking (2024)
• 2.4 Global ADCC Enhanced Antibody Sales Volume by Company Players (2020-2025)
• 2.5 Global ADCC Enhanced Antibody Average Price by Company (2020-2025)
• 2.6 Key Manufacturers ADCC Enhanced Antibody Manufacturing Base and Headquarters
• 2.7 Key Manufacturers ADCC Enhanced Antibody Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of ADCC Enhanced Antibody
• 2.9 ADCC Enhanced Antibody Market Competitive Analysis
  • 2.9.1 ADCC Enhanced Antibody Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by ADCC Enhanced Antibody Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ADCC Enhanced Antibody as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Monospecific Antibody
  • 3.1.2 Polyspecific Antibody
  • 3.1.3 Fc Fusion Protein
  • 3.1.4 Antibody Fusion Protein
• 3.2 Global ADCC Enhanced Antibody Sales Value by Type
  • 3.2.1 Global ADCC Enhanced Antibody Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global ADCC Enhanced Antibody Sales Value, by Type (2020-2031)
  • 3.2.3 Global ADCC Enhanced Antibody Sales Value, by Type (%) (2020-2031)
• 3.3 Global ADCC Enhanced Antibody Sales Volume by Type
  • 3.3.1 Global ADCC Enhanced Antibody Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global ADCC Enhanced Antibody Sales Volume, by Type (2020-2031)
  • 3.3.3 Global ADCC Enhanced Antibody Sales Volume, by Type (%) (2020-2031)
• 3.4 Global ADCC Enhanced Antibody Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Clinic
  • 4.1.3 Others
• 4.2 Global ADCC Enhanced Antibody Sales Value by Application
  • 4.2.1 Global ADCC Enhanced Antibody Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global ADCC Enhanced Antibody Sales Value, by Application (2020-2031)
  • 4.2.3 Global ADCC Enhanced Antibody Sales Value, by Application (%) (2020-2031)
• 4.3 Global ADCC Enhanced Antibody Sales Volume by Application
  • 4.3.1 Global ADCC Enhanced Antibody Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global ADCC Enhanced Antibody Sales Volume, by Application (2020-2031)
  • 4.3.3 Global ADCC Enhanced Antibody Sales Volume, by Application (%) (2020-2031)
• 4.4 Global ADCC Enhanced Antibody Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global ADCC Enhanced Antibody Sales Value by Region
  • 5.1.1 Global ADCC Enhanced Antibody Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global ADCC Enhanced Antibody Sales Value by Region (2020-2025)
  • 5.1.3 Global ADCC Enhanced Antibody Sales Value by Region (2026-2031)
  • 5.1.4 Global ADCC Enhanced Antibody Sales Value by Region (%), (2020-2031)
• 5.2 Global ADCC Enhanced Antibody Sales Volume by Region
  • 5.2.1 Global ADCC Enhanced Antibody Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global ADCC Enhanced Antibody Sales Volume by Region (2020-2025)
  • 5.2.3 Global ADCC Enhanced Antibody Sales Volume by Region (2026-2031)
  • 5.2.4 Global ADCC Enhanced Antibody Sales Volume by Region (%), (2020-2031)
• 5.3 Global ADCC Enhanced Antibody Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America ADCC Enhanced Antibody Sales Value, 2020-2031
  • 5.4.2 North America ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe ADCC Enhanced Antibody Sales Value, 2020-2031
  • 5.5.2 Europe ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific ADCC Enhanced Antibody Sales Value, 2020-2031
  • 5.6.2 Asia Pacific ADCC Enhanced Antibody Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America ADCC Enhanced Antibody Sales Value, 2020-2031
  • 5.7.2 South America ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa ADCC Enhanced Antibody Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions ADCC Enhanced Antibody Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions ADCC Enhanced Antibody Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions ADCC Enhanced Antibody Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.3.2 United States ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.4.2 Europe ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.5.2 China ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.6.2 Japan ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.7.2 South Korea ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.8.2 Southeast Asia ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India ADCC Enhanced Antibody Sales Value, 2020-2031
  • 6.9.2 India ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India ADCC Enhanced Antibody Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 MacroGenics
  • 7.1.1 MacroGenics Company Information
  • 7.1.2 MacroGenics Introduction and Business Overview
  • 7.1.3 MacroGenics ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 MacroGenics ADCC Enhanced Antibody Product Offerings
  • 7.1.5 MacroGenics Recent Development
• 7.2 Roche Holding AG
  • 7.2.1 Roche Holding AG Company Information
  • 7.2.2 Roche Holding AG Introduction and Business Overview
  • 7.2.3 Roche Holding AG ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Roche Holding AG ADCC Enhanced Antibody Product Offerings
  • 7.2.5 Roche Holding AG Recent Development
• 7.3 Novartis AG
  • 7.3.1 Novartis AG Company Information
  • 7.3.2 Novartis AG Introduction and Business Overview
  • 7.3.3 Novartis AG ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Novartis AG ADCC Enhanced Antibody Product Offerings
  • 7.3.5 Novartis AG Recent Development
• 7.4 C.H. Boehringer Sohn
  • 7.4.1 C.H. Boehringer Sohn Company Information
  • 7.4.2 C.H. Boehringer Sohn Introduction and Business Overview
  • 7.4.3 C.H. Boehringer Sohn ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 C.H. Boehringer Sohn ADCC Enhanced Antibody Product Offerings
  • 7.4.5 C.H. Boehringer Sohn Recent Development
• 7.5 Puma Biotechnology
  • 7.5.1 Puma Biotechnology Company Information
  • 7.5.2 Puma Biotechnology Introduction and Business Overview
  • 7.5.3 Puma Biotechnology ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Puma Biotechnology ADCC Enhanced Antibody Product Offerings
  • 7.5.5 Puma Biotechnology Recent Development
• 7.6 Pfizer
  • 7.6.1 Pfizer Company Information
  • 7.6.2 Pfizer Introduction and Business Overview
  • 7.6.3 Pfizer ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Pfizer ADCC Enhanced Antibody Product Offerings
  • 7.6.5 Pfizer Recent Development
• 7.7 Daiichi Sankyo
  • 7.7.1 Daiichi Sankyo Company Information
  • 7.7.2 Daiichi Sankyo Introduction and Business Overview
  • 7.7.3 Daiichi Sankyo ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Daiichi Sankyo ADCC Enhanced Antibody Product Offerings
  • 7.7.5 Daiichi Sankyo Recent Development
• 7.8 Takeda Pharmaceutical
  • 7.8.1 Takeda Pharmaceutical Company Information
  • 7.8.2 Takeda Pharmaceutical Introduction and Business Overview
  • 7.8.3 Takeda Pharmaceutical ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Takeda Pharmaceutical ADCC Enhanced Antibody Product Offerings
  • 7.8.5 Takeda Pharmaceutical Recent Development
• 7.9 Jazz Pharmaceuticals
  • 7.9.1 Jazz Pharmaceuticals Company Information
  • 7.9.2 Jazz Pharmaceuticals Introduction and Business Overview
  • 7.9.3 Jazz Pharmaceuticals ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Jazz Pharmaceuticals ADCC Enhanced Antibody Product Offerings
  • 7.9.5 Jazz Pharmaceuticals Recent Development
• 7.10 Merus NV
  • 7.10.1 Merus NV Company Information
  • 7.10.2 Merus NV Introduction and Business Overview
  • 7.10.3 Merus NV ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Merus NV ADCC Enhanced Antibody Product Offerings
  • 7.10.5 Merus NV Recent Development
• 7.11 Hengrui Medicine
  • 7.11.1 Hengrui Medicine Company Information
  • 7.11.2 Hengrui Medicine Introduction and Business Overview
  • 7.11.3 Hengrui Medicine ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Hengrui Medicine ADCC Enhanced Antibody Product Offerings
  • 7.11.5 Hengrui Medicine Recent Development
• 7.12 Sansheng Guojian
  • 7.12.1 Sansheng Guojian Company Information
  • 7.12.2 Sansheng Guojian Introduction and Business Overview
  • 7.12.3 Sansheng Guojian ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Sansheng Guojian ADCC Enhanced Antibody Product Offerings
  • 7.12.5 Sansheng Guojian Recent Development
• 7.13 RemeGen Biopharma
  • 7.13.1 RemeGen Biopharma Company Information
  • 7.13.2 RemeGen Biopharma Introduction and Business Overview
  • 7.13.3 RemeGen Biopharma ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 RemeGen Biopharma ADCC Enhanced Antibody Product Offerings
  • 7.13.5 RemeGen Biopharma Recent Development
• 7.14 Dizal (Jiangsu) Pharmaceutical
  • 7.14.1 Dizal (Jiangsu) Pharmaceutical Company Information
  • 7.14.2 Dizal (Jiangsu) Pharmaceutical Introduction and Business Overview
  • 7.14.3 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Offerings
  • 7.14.5 Dizal (Jiangsu) Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 ADCC Enhanced Antibody Industrial Chain
• 8.2 ADCC Enhanced Antibody Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 ADCC Enhanced Antibody Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 ADCC Enhanced Antibody Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer

List of Tables

Table 1. ADCC Enhanced Antibody Market Trends

Table 2. ADCC Enhanced Antibody Market Drivers & Opportunity

Table 3. ADCC Enhanced Antibody Market Challenges

Table 4. ADCC Enhanced Antibody Market Restraints

Table 5. Global ADCC Enhanced Antibody Revenue by Company (2020-2025) & (US$ Million)

Table 6. Global ADCC Enhanced Antibody Revenue Market Share by Company (2020-2025)

Table 7. Global ADCC Enhanced Antibody Sales Volume by Company (2020-2025) & (K Units)

Table 8. Global ADCC Enhanced Antibody Sales Volume Market Share by Company (2020-2025)

Table 9. Global Market ADCC Enhanced Antibody Price by Company (2020-2025) & (US$/Unit)

Table 10. Key Manufacturers ADCC Enhanced Antibody Manufacturing Base and Headquarters

Table 11. Key Manufacturers ADCC Enhanced Antibody Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of ADCC Enhanced Antibody

Table 13. Global ADCC Enhanced Antibody Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ADCC Enhanced Antibody as of 2024)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global ADCC Enhanced Antibody Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)

Table 17. Global ADCC Enhanced Antibody Sales Value by Type (2020-2025) & (US$ Million)

Table 18. Global ADCC Enhanced Antibody Sales Value by Type (2026-2031) & (US$ Million)

Table 19. Global ADCC Enhanced Antibody Sales Market Share in Value by Type (2020-2025)

Table 20. Global ADCC Enhanced Antibody Sales Market Share in Value by Type (2026-2031)

Table 21. Global ADCC Enhanced Antibody Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)

Table 22. Global ADCC Enhanced Antibody Sales Volume by Type (2020-2025) & (K Units)

Table 23. Global ADCC Enhanced Antibody Sales Volume by Type (2026-2031) & (K Units)

Table 24. Global ADCC Enhanced Antibody Sales Volume Market Share by Type (2020-2025)

Table 25. Global ADCC Enhanced Antibody Sales Volume Market Share by Type (2026-2031)

Table 26. Global ADCC Enhanced Antibody Price by Type (2020-2025) & (US$/Unit)

Table 27. Global ADCC Enhanced Antibody Price by Type (2026-2031) & (US$/Unit)

Table 28. Global ADCC Enhanced Antibody Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)

Table 29. Global ADCC Enhanced Antibody Sales Value by Application (2020-2025) & (US$ Million)

Table 30. Global ADCC Enhanced Antibody Sales Value by Application (2026-2031) & (US$ Million)

Table 31. Global ADCC Enhanced Antibody Sales Market Share in Value by Application (2020-2025)

Table 32. Global ADCC Enhanced Antibody Sales Market Share in Value by Application (2026-2031)

Table 33. Global ADCC Enhanced Antibody Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)

Table 34. Global ADCC Enhanced Antibody Sales Volume by Application (2020-2025) & (K Units)

Table 35. Global ADCC Enhanced Antibody Sales Volume by Application (2026-2031) & (K Units)

Table 36. Global ADCC Enhanced Antibody Sales Volume Market Share by Application (2020-2025)

Table 37. Global ADCC Enhanced Antibody Sales Volume Market Share by Application (2026-2031)

Table 38. Global ADCC Enhanced Antibody Price by Application (2020-2025) & (US$/Unit)

Table 39. Global ADCC Enhanced Antibody Price by Application (2026-2031) & (US$/Unit)

Table 40. Global ADCC Enhanced Antibody Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)

Table 41. Global ADCC Enhanced Antibody Sales Value by Region (2020-2025) & (US$ Million)

Table 42. Global ADCC Enhanced Antibody Sales Value by Region (2026-2031) & (US$ Million)

Table 43. Global ADCC Enhanced Antibody Sales Value by Region (2020-2025) & (%)

Table 44. Global ADCC Enhanced Antibody Sales Value by Region (2026-2031) & (%)

Table 45. Global ADCC Enhanced Antibody Sales Volume by Region (K Units): 2020 VS 2024 VS 2031

Table 46. Global ADCC Enhanced Antibody Sales Volume by Region (2020-2025) & (K Units)

Table 47. Global ADCC Enhanced Antibody Sales Volume by Region (2026-2031) & (K Units)

Table 48. Global ADCC Enhanced Antibody Sales Volume by Region (2020-2025) & (%)

Table 49. Global ADCC Enhanced Antibody Sales Volume by Region (2026-2031) & (%)

Table 50. Global ADCC Enhanced Antibody Average Price by Region (2020-2025) & (US$/Unit)

Table 51. Global ADCC Enhanced Antibody Average Price by Region (2026-2031) & (US$/Unit)

Table 52. Key Countries/Regions ADCC Enhanced Antibody Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031

Table 53. Key Countries/Regions ADCC Enhanced Antibody Sales Value, (2020-2025) & (US$ Million)

Table 54. Key Countries/Regions ADCC Enhanced Antibody Sales Value, (2026-2031) & (US$ Million)

Table 55. Key Countries/Regions ADCC Enhanced Antibody Sales Volume, (2020-2025) & (K Units)

Table 56. Key Countries/Regions ADCC Enhanced Antibody Sales Volume, (2026-2031) & (K Units)

Table 57. MacroGenics Company Information

Table 58. MacroGenics Introduction and Business Overview

Table 59. MacroGenics ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 60. MacroGenics ADCC Enhanced Antibody Product Offerings

Table 61. MacroGenics Recent Development

Table 62. Roche Holding AG Company Information

Table 63. Roche Holding AG Introduction and Business Overview

Table 64. Roche Holding AG ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 65. Roche Holding AG ADCC Enhanced Antibody Product Offerings

Table 66. Roche Holding AG Recent Development

Table 67. Novartis AG Company Information

Table 68. Novartis AG Introduction and Business Overview

Table 69. Novartis AG ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 70. Novartis AG ADCC Enhanced Antibody Product Offerings

Table 71. Novartis AG Recent Development

Table 72. C.H. Boehringer Sohn Company Information

Table 73. C.H. Boehringer Sohn Introduction and Business Overview

Table 74. C.H. Boehringer Sohn ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 75. C.H. Boehringer Sohn ADCC Enhanced Antibody Product Offerings

Table 76. C.H. Boehringer Sohn Recent Development

Table 77. Puma Biotechnology Company Information

Table 78. Puma Biotechnology Introduction and Business Overview

Table 79. Puma Biotechnology ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 80. Puma Biotechnology ADCC Enhanced Antibody Product Offerings

Table 81. Puma Biotechnology Recent Development

Table 82. Pfizer Company Information

Table 83. Pfizer Introduction and Business Overview

Table 84. Pfizer ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 85. Pfizer ADCC Enhanced Antibody Product Offerings

Table 86. Pfizer Recent Development

Table 87. Daiichi Sankyo Company Information

Table 88. Daiichi Sankyo Introduction and Business Overview

Table 89. Daiichi Sankyo ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. Daiichi Sankyo ADCC Enhanced Antibody Product Offerings

Table 91. Daiichi Sankyo Recent Development

Table 92. Takeda Pharmaceutical Company Information

Table 93. Takeda Pharmaceutical Introduction and Business Overview

Table 94. Takeda Pharmaceutical ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 95. Takeda Pharmaceutical ADCC Enhanced Antibody Product Offerings

Table 96. Takeda Pharmaceutical Recent Development

Table 97. Jazz Pharmaceuticals Company Information

Table 98. Jazz Pharmaceuticals Introduction and Business Overview

Table 99. Jazz Pharmaceuticals ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 100. Jazz Pharmaceuticals ADCC Enhanced Antibody Product Offerings

Table 101. Jazz Pharmaceuticals Recent Development

Table 102. Merus NV Company Information

Table 103. Merus NV Introduction and Business Overview

Table 104. Merus NV ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 105. Merus NV ADCC Enhanced Antibody Product Offerings

Table 106. Merus NV Recent Development

Table 107. Hengrui Medicine Company Information

Table 108. Hengrui Medicine Introduction and Business Overview

Table 109. Hengrui Medicine ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 110. Hengrui Medicine ADCC Enhanced Antibody Product Offerings

Table 111. Hengrui Medicine Recent Development

Table 112. Sansheng Guojian Company Information

Table 113. Sansheng Guojian Introduction and Business Overview

Table 114. Sansheng Guojian ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 115. Sansheng Guojian ADCC Enhanced Antibody Product Offerings

Table 116. Sansheng Guojian Recent Development

Table 117. RemeGen Biopharma Company Information

Table 118. RemeGen Biopharma Introduction and Business Overview

Table 119. RemeGen Biopharma ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 120. RemeGen Biopharma ADCC Enhanced Antibody Product Offerings

Table 121. RemeGen Biopharma Recent Development

Table 122. Dizal (Jiangsu) Pharmaceutical Company Information

Table 123. Dizal (Jiangsu) Pharmaceutical Introduction and Business Overview

Table 124. Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 125. Dizal (Jiangsu) Pharmaceutical ADCC Enhanced Antibody Product Offerings

Table 126. Dizal (Jiangsu) Pharmaceutical Recent Development

Table 127. Key Raw Materials Lists

Table 128. Raw Materials Key Suppliers Lists

Table 129. ADCC Enhanced Antibody Downstream Customers

Table 130. ADCC Enhanced Antibody Distributors List

Table 131. Research Programs/Design for This Report

Table 132. Key Data Information from Secondary Sources

Table 133. Key Data Information from Primary Sources

List of Figures

Figure 1. ADCC Enhanced Antibody Product Picture

Figure 2. Global ADCC Enhanced Antibody Sales Value, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Global ADCC Enhanced Antibody Sales Value (2020-2031) & (US$ Million)

Figure 4. Global ADCC Enhanced Antibody Sales Volume (2020-2031) & (K Units)

Figure 5. Global ADCC Enhanced Antibody Sales Price (2020-2031) & (US$/Unit)

Figure 6. ADCC Enhanced Antibody Report Years Considered

Figure 7. Global ADCC Enhanced Antibody Players Revenue Ranking (2024) & (US$ Million)

Figure 8. Global ADCC Enhanced Antibody Players Sales Volume Ranking (2024) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by ADCC Enhanced Antibody Revenue in 2024

Figure 10. ADCC Enhanced Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 11. Monospecific Antibody Picture

Figure 12. Polyspecific Antibody Picture

Figure 13. Fc Fusion Protein Picture

Figure 14. Antibody Fusion Protein Picture

Figure 15. Global ADCC Enhanced Antibody Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)

Figure 16. Global ADCC Enhanced Antibody Sales Value Market Share by Type, 2024 & 2031

Figure 17. Global ADCC Enhanced Antibody Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)

Figure 18. Global ADCC Enhanced Antibody Sales Volume Market Share by Type, 2024 & 2031

Figure 19. Global ADCC Enhanced Antibody Price by Type (2020-2031) & (US$/Unit)

Figure 20. Product Picture of Hospital

Figure 21. Product Picture of Clinic

Figure 22. Product Picture of Others

Figure 23. Global ADCC Enhanced Antibody Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)

Figure 24. Global ADCC Enhanced Antibody Sales Value Market Share by Application, 2024 & 2031

Figure 25. Global ADCC Enhanced Antibody Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)

Figure 26. Global ADCC Enhanced Antibody Sales Volume Market Share by Application, 2024 & 2031

Figure 27. Global ADCC Enhanced Antibody Price by Application (2020-2031) & (US$/Unit)

Figure 28. North America ADCC Enhanced Antibody Sales Value (2020-2031) & (US$ Million)

Figure 29. North America ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031

Figure 30. Europe ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 31. Europe ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031

Figure 32. Asia Pacific ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 33. Asia Pacific ADCC Enhanced Antibody Sales Value by Region (%), 2024 VS 2031

Figure 34. South America ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 35. South America ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031

Figure 36. Middle East & Africa ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 37. Middle East & Africa ADCC Enhanced Antibody Sales Value by Country (%), 2024 VS 2031

Figure 38. Key Countries/Regions ADCC Enhanced Antibody Sales Value (%), (2020-2031)

Figure 39. Key Countries/Regions ADCC Enhanced Antibody Sales Volume (%), (2020-2031)

Figure 40. United States ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 41. United States ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 42. United States ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 43. Europe ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 44. Europe ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 45. Europe ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 46. China ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 47. China ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 48. China ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 49. Japan ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 50. Japan ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 51. Japan ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 52. South Korea ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 53. South Korea ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 54. South Korea ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 55. Southeast Asia ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 56. Southeast Asia ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 57. Southeast Asia ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 58. India ADCC Enhanced Antibody Sales Value, (2020-2031) & (US$ Million)

Figure 59. India ADCC Enhanced Antibody Sales Value by Type (%), 2024 VS 2031

Figure 60. India ADCC Enhanced Antibody Sales Value by Application (%), 2024 VS 2031

Figure 61. ADCC Enhanced Antibody Industrial Chain

Figure 62. ADCC Enhanced Antibody Manufacturing Cost Structure

Figure 63. Channels of Distribution (Direct Sales, and Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed